Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
Evaluation of the Safety and Efficacy of CR-CHOP Treatment in Newly Diagnosed Double-Expressor DLBCL with Other Molecular Subtypes
Trial Details
- NCT ID
- NCT06891157
- Phase
- PHASE2
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- RECRUITING
- Cancer Type
- Lymphoma
- Interventions
- Locations (sample)
- Nanjing, Jiangsu, China|32.06167,118.77778
Key Eligibility Criteria
- Patients must meet all of the following inclusion criteria to be eligible for enrollment:
- ≥18 years of age;
- Diffuse large B-cell lymphoma diagnosed by pathological diagnosis according to WHO 2016 classification criteria;
- Molecular subtyping, determined through high-throughput sequencing of pathological tissue or peripheral blood, is categorized as the "Other" subtype;
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →